• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vivos Therapeutics Inc.

    9/24/24 2:59:09 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care
    Get the next $VVOS alert in real time by email
    SC 13G 1 g084445_sc13g.htm SC 13G

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    Vivos Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    92859E207

    (CUSIP Number)

     

    September 19, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 92859E207   13G   Page 2 of 10 Pages

     

    1. NAMES OF REPORTING PERSONS

    Ionic Ventures, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    412,064 (1)  

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    412,064 (1)  

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    412,064 (1)   

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.7% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

      (1) As more fully described in Item 4 of this Statement on Schedule 13G (this “Schedule 13G”), such shares and percentage are based on 4,765,300 outstanding shares of common stock, par value $0.0001 per share, of the issuer (the “Common Stock”), as reported in the prospectus supplement to the registration statement on Form S-3 (File No. 333-262554), filed by the issuer with the U.S. Securities and Exchange Commission on September 20, 2024 (the “Prospectus Supplement”).

     

     

    CUSIP No. 92859E207   13G   Page 3 of 10 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Ionic Management, LLC 

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    412,064 (1)   

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    412,064 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    412,064 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.7% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

      (1) As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 4,765,300 shares of Common Stock outstanding, as reported in the Prospectus Supplement.

     

     

    CUSIP No. 92859E207   13G   Page 4 of 10 Pages

     

    1. NAMES OF REPORTING PERSONS

    Brendan O’Neil
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    412,064 (1) 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    412,064 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    412,064 (1)  

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.7% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

      (1) As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 4,765,300 shares of Common Stock outstanding, as reported in the Prospectus Supplement.

     

     

    CUSIP No. 92859E207   13G   Page 5 of 10 Pages

     

    1. NAMES OF REPORTING PERSONS

    Keith Coulston
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    412,064 (1)  

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    412,064 (1)  

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    412,064 (1)   

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.7% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

      (1) As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 4,765,300 shares of Common Stock outstanding, as reported in the Prospectus Supplement.

     

     

    CUSIP No. 92859E207   13G   Page 6 of 10 Pages

     

    Item 1(a). Name of Issuer:

     

    Vivos Therapeutics, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    The Issuer’s principal executive office is located at 7921 Southpark Plaza, Suite 210, Littleton, CO 80120.

     

    Item 2(a). Names of Persons Filing:

     

      (i) Ionic Ventures LLC, a California limited liability company (“Ionic”);
       
      (ii) Ionic Management, LLC, a Delaware limited liability company (“Ionic Management”);
       
      (iii) Brendan O’Neil (“Mr. O’Neil”); and
       
      (iv) Keith Coulston (“Mr. Coulston”).

     

    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which such Reporting Persons have agreed to file this Schedule 13G and all subsequent amendments to the Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    The filing of this Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of the common stock reported herein.  

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is 3053 Fillmore St, Suite 256, San Francisco, CA 94123.

     

    Item 2(c). Citizenship:

     

    Ionic is a limited liability company organized under the laws of the State of California. Ionic Management is a limited liability company organized under the laws of the State of Delaware. Each of Mr. Coulston and Mr. O’Neil is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities:

     

    The title of the class of securities to which this Schedule 13G relates is the Issuer’s common stock, par value $0.0001 per share (the “Common Stock”).

     

     

     

    CUSIP No. 92859E207   13G   Page 7 of 10 Pages

     

    Item 2(e). CUSIP Number: 92859E207

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on 4,765,300 shares of Common Stock outstanding, as reported in the prospectus supplement to the registration statement on Form S-3 (File No. 333-262554), filed by the Issuer with the U.S. Securities and Exchange Commission on September 20, 2024.

     

    As of September 24, 2024, Ionic is the beneficial owner of 412,064 shares of Common Stock (the “Shares”). Ionic has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by its manager, Ionic Management. Each of the managers of Ionic Management, Mr. O’Neil and Mr. Coulston, has shared power to vote and/or dispose of the Shares beneficially owned by Ionic and Ionic Management. Neither Mr. O’Neil nor Mr. Coulston directly owns the Shares. By reason of the provisions of Rule 13d-3 of the Act, each of Mr. O’Neil and Mr. Coulston may be deemed to beneficially own the Shares which are beneficially owned by each of Ionic and Ionic Management, and Ionic Management may be deemed to beneficially own the Shares which are beneficially owned by Ionic.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

    CUSIP No. 92859E207   13G   Page 8 of 10 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    See Exhibit 1 filed herewith.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below each of the Reporting Persons certify that, to the best of each of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.  

     

     

     

    CUSIP No. 92859E207   13G   Page 9 of 10 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

     

    Date: September 24, 2024 IONIC VENTURES, LLC
       
      By:  Ionic Management, LLC,
         its Manager
       
      By:  /s/ Keith Coulston
         Name: Keith Coulston
         Title: Manager
       
      IONIC MANAGEMENT, LLC
       
      By:  /s/ Keith Coulston
         Name: Keith Coulston
         Title: Manager
         
      /s/ Brendan O’Neil
      Brendan O’Neil
         
      /s/ Keith Coulston
      Keith Coulston

     

     

    CUSIP No. 92859E207   13G   Page 10 of 10 Pages

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT  

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

     

    Date: September 24, 2024 IONIC VENTURES, LLC
       
      By: Ionic Management, LLC,
             its Manager
       
      By:  /s/ Keith Coulston
         Name: Keith Coulston
         Title: Manager
       
      IONIC MANAGEMENT, LLC
       
      By:  /s/ Keith Coulston
         Name: Keith Coulston
         Title: Manager
         
      /s/ Brendan O’Neil
      Brendan O’Neil
         
      /s/ Keith Coulston
      Keith Coulston

      

     

     

    Get the next $VVOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VVOS

    DatePrice TargetRatingAnalyst
    8/13/2021$11.00 → $10.00Buy
    Roth Capital
    More analyst ratings

    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in childr

      5/15/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

      LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the

      5/14/25 9:15:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

      By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating assets of The Sleep Center of Nevada ("SCN"), the largest operator of medical sleep centers in Nevada. Significant Vivos investor New Seneca Partners, Inc., a leading Nor

      4/16/25 8:30:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Financials

    Live finance-specific insights

    See more
    • Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in childr

      5/15/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

      LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the

      5/14/25 9:15:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

      Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended D

      3/31/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

      Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously

      8/13/21 1:08:07 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

      Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously

      5/18/21 10:44:01 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

      SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

      11/14/24 4:49:30 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

      SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

      11/14/24 4:05:24 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vivos Therapeutics Inc.

      SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)

      9/24/24 2:59:09 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Huntsman Ronald Kirk

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      11/27/24 4:47:13 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Amman Bradford K.

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      11/27/24 4:43:54 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Sokolow Leonard J

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      6/28/24 8:53:50 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    SEC Filings

    See more
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      6/6/25 5:19:55 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      5/23/25 8:00:22 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      5/15/25 5:25:05 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care